Extended Data Fig. 4: Induction of heterologous neutralizing antibodies in immunized macaques. | Nature Medicine

Extended Data Fig. 4: Induction of heterologous neutralizing antibodies in immunized macaques.

From: A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques

Extended Data Fig. 4

a. Serum titers of neutralizing antibodies against a heterologous tier-1a Env (SF162). b. Serum titers of neutralizing antibodies against a heterologous tier-1b Env (BaL). c. Neutralization of SF162 in the two vaccine subgroups. d. Neutralization of BaL in the two vaccine subgroups. The asterisk denotes a p value <0.05, as assessed by two-tailed unpaired t-test. e. Neutralization of the tier-2 Env JR-FL in the two vaccine subgroups. f. Neutralization of the tier-2 Env AD8 in the two vaccine subgroups. g. Serum titers of neutralizing antibodies against a panel of heterologous tier-2 Envs at week 58 in the two vaccine subgroups. Neutralization assays were performed using pseudoviruses on TZM-bl cells. The sequence and timing of immunizations are indicated by color-coded triangles on the top. Subgroup 1 received 5 mRNA and 5 protein immunizations; subgroup 2 received 8 mRNA and 2 protein immunizations.

Back to article page